Dr. David Braun discusses HPK1 inhibition as a novel immunotherapy approach targeting an intracellular immune “brake” in kidney cancer. Early data with NDI-101150 show encouraging clinical benefit in heavily pretreated patients with manageable toxicity and potential for combination use. He also highlights upcoming LITESPARK-022 and LITESPARK-011 data, which may further expand HIF2α-targeted strategies in RCC.
Belzutifan Moves Earlier in Kidney Cancer Care
Dr. Laurence Albiges outlines how belzutifan is reshaping kidney cancer treatment across disease stages. In the adjuvant setting, adding belzutifan
